Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
This finding could potentially offer a way to blunt Zika’s devastating impact.
Researchers at George Washington University take a look.
Starting treatment within four months of infection also predicted a better resurgence of CD4 cells.
The high proportion of individuals starting treatment with drug resistance already warrants changing the recommended first-line therapy.
Merck’s next-generation NNRTI doravirine (MK-1439) suppresses HIV as well as Sustiva (efavirenz) and leads to half the rate of side effects.
Merck’s investigatory non-nuke MK-1439 proved safe and well tolerated—and it displayed robust antiviral activity in a small early trial.
The U.S. Food and Drug Administration (FDA) has approved Edurant (rilpivirine), a new non-nucleoside reverse transcriptase inhibitor (NNRTI)
Lersivirine, ViiV Healthcare’s experimental NNRTI, achieves similar rates of viral load suppression compared with Sustiva (efavirenz).
The U.S. Food and Drug Administration (FDA) has approved a new HIV-fighting non-nucleoside reverse transcriptase inhibitor (NNRTI) called...
ViiV Healthcare announced that the U.S. Food and Drug Administration has placed a hold on the development of a non-nucleoside reverse...
People who didn’t adhere to their antiretroviral (ARV) treatment regimen, or who started treatment with a high viral load, were more likely to...
Rilpivirine (TMC278) was similar to Sustiva (efavirenz) in two large clinical trials but demonstrated much fewer central nervous system (CNS)...
In the past month, two companies shelved their once-promising experimental HIV drugs, citing the challenging nature of bringing a...
About one of every six new HIV cases diagnosed in 2007 involved virus with antiretroviral (ARV) drug-resistance mutations.
The number of new HIV infections with virus resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) could rise significantly in...
Regimens containing a protease inhibitor (PI) might be less prone to drug resistance upon treatment failure than regimens containing a non-nuc...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.